You are here

Article Text

Article menu

Download PDFPDF

Scientific Abstracts
Poster Tours
Small vessels on fire
POS0246 SEQUENTIAL RITUXIMAB AND MEPOLIZUMAB IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Free
  1. A. Bettiol1,
  2. M. L. Urban1,
  3. F. Bello1,
  4. D. Fiori1,
  5. I. Mattioli1,
  6. G. Lopalco2,
  7. F. Iannone2,
  8. A. Egan3,
  9. L. Moroni4,
  10. L. Dagna4,
  11. M. Caminati5,
  12. S. Negrini6,
  13. P. Cameli7,
  14. M. Folci8,
  15. P. Toniati9,
  16. R. Padoan10,
  17. O. Flossmann11,
  18. R. Solans-Laqué12,
  19. L. Losappio13,
  20. J. Schroeder13,
  21. M. André14,
  22. L. Moi15,
  23. P. Parronchi1,
  24. F. Conti16,
  25. S. Sciascia17,
  26. D. Jayne3,
  27. A. Vaglio18,
  28. G. Emmi1
  29. on behalf of European EGPA Study Group
  1. 1University of Florence, Department of Experimental and Clinical Medicine, Firenze, Italy
  2. 2University of Bari and Polyclinic Hospital, Rheumatology Unit, Department of Emergency and Organ Transplantation, Bari, Italy
  3. 3University of Cambridge, Department of Medicine, Cambridge, United Kingdom
  4. 4IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milan, Italy
  5. 5University of Verona and Verona University Hospital, Department of Medicine, Verona, Italy
  6. 6IRCCS Ospedale Policlinico San Martino and University of Genoa, Department of Internal Medicine, Genoa, Italy
  7. 7University of Siena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences and Neurosciences, Siena, Italy
  8. 8IRCCS Humanitas Research Hospital and Humanitas University, Department of Biomedical Sciences, Milan, Italy
  9. 9ASST Spedali Civili of Brescia, Rheumatology and Clinical Immunology Unit, Brescia, Italy
  10. 10University of Padova, Division of Rheumatology, Department of Medicine, Padova, Italy
  11. 11Royal Berkshire Hospital, DeDepartment of Nephrology, Reading, United Kingdom
  12. 12Vall d’Hebron Hopsital, Autoimmune Systemic Diseases Unit, Barcelona, Spain
  13. 13ASST Grande Ospedale Metropolitano Niguarda, Allergy and Immunology Unit, Milan, Italy
  14. 14Hôpital Gabriel Montpied, Service de Médecine Interne, Clermont-Ferrand, France
  15. 15Lausanne University Hospital, Division of Immunology and Allergy, Lausanne, Switzerland
  16. 16Sapienza University, Department of Experimental Medicine, Rome, Italy
  17. 17St Giovanni Bosco Hospital and the University of Turin, Department of Clinical and Biological Sciences, Turin, Italy
  18. 18University of Florence and Meyer Children’s Hospital, Department of Biomedical Experimental and Clinical Sciences “Mario Serio”, Florence, Italy

Abstract

Background Rituximab (RTX) is an effective remission-induction treatment in ANCA-associated vasculitides (AAVs). Some reports have suggested that it might be effective also in Eosinophilic Granulomatosis with Polyangiitis (EGPA), to induce and maintain remission of vasculitic manifestations [1,2]. However, its effects for preventing respiratory relapses seem to be poor. Mepolizumab (Mepo) (both 100 and 300mg/month) is effective in improving respiratory manifestations and lung function, while partially controlling also systemic activity [3,4]. Isolated case reports further indicate that the sequential therapy with RTX and Mepo might be effective [5-7].

Objectives The study aimed to investigate the efficacy and safety of a therapeutic regimen based on sequential RTX and Mepo for the control of EGPA.

Methods A multicenter, retrospective, cohort study was conducted on adult patients diagnosed with EGPA according to the ACR classification criteria [8] or MIRRA trial criteria [3]. Only patients who received induction therapy with RTX (any dosage), and subsequent treatment with Mepo (100-300 mg/4 weeks) within 12 months from last RTX administration were included. Patients receiving other induction therapies between RTX and Mepo were excluded. The effectiveness of sequential RTX and Mepo was assessed in terms of disease activity (by the Birmingham Vasculitis Activity Score, BVAS) and daily corticosteroid dosage. Safety data were also collected.

Results Thirty-four EGPA patients treated with sequential RTX and Mepo were included (59% females, median age of 51 years (IQR 40-58); 41% ANCA positive).

In most cases (26/34; 76%), RTX was started at the dosage of 1g q2w, and all except two patients had active disease at time of RTX beginning [median BVAS of 9 (IQR 6-14)]. Specifically, most patients started RTX for the control of systemic manifestations (19/34; 56%), or of both systemic and respiratory symptoms (11/34; 32%). All except one patient were receiving oral corticosteroids, at a median dosage of 25 mg/day (10-38).

Mepo was started after a median of 14 months (6-23) from RTX initiation and after a median of 5 months (IQR 3-11) from the last RTX administration. Mepo was used at the dosage of 100mg/4 weeks in 32/34 (94%), mostly for the control of respiratory manifestations (25/34, 74%). At the time of starting Mepo, the median BVAS was 4 (2-8), and median prednisolone dose 10 mg/day (7-15). After a median follow-up of 28 months (IQR 23-33) from starting Mepo, the median BVAS decreased to 1.5 (IQR 0-4) and the median corticosteroid dosage to 5 mg/day (2.5-5), with 7/34 (21%) patients being off steroids. At last follow-up, most patients were off-RTX (28/34), typically due to stable disease remission (20/34; 59%).

Both RTX and Mepo were well-tolerated; 5 patients had adverse events on RTX (none serious), and 5 on Mepo (including one serious infection).

Conclusion Sequential use of RTX and Mepo seems to be effective for remission induction and maintenance in EGPA.

References [1]Emmi, Ann Rheum Dis, 2018

[2]Teixeira, RMD Open, 2019 3. Wechsler, NEJM, 2017

[4]Bettiol, Arthritis Rheumatol, 2021

[5]Shiroshita, Respir Med Case Rep, 2018

[6]Higashitani, Mod Rheumatol Case Rep, 2021

[7]Afiari, Cureus 2020

[8]Masi, Arthritis Rheum, 1990

View this table:
Table 1.

Effectiveness of sequential RTX and Mepo in the 34 patients included in the study

Disclosure of Interests Alessandra Bettiol: None declared, Maria Letizia Urban: None declared, Federica Bello: None declared, Davide Fiori: None declared, Irene Mattioli: None declared, Giuseppe Lopalco: None declared, Florenzo Iannone: None declared, Allyson Egan: None declared, Luca Moroni: None declared, Lorenzo Dagna Consultant of: Consultation honoraria from GSK outside the current work, Marco Caminati: None declared, Simone Negrini: None declared, Paolo Cameli: None declared, Marco Folci: None declared, Paola Toniati: None declared, Roberto Padoan: None declared, Oliver Flossmann: None declared, Roser Solans-Laqué: None declared, Laura Losappio: None declared, Jan Schroeder Consultant of: Advisory Board fees from AstraZeneca and GSK, Marc André: None declared, Laura Moi: None declared, paola parronchi Consultant of: Consultation honoraria from GSK and Novartis, Fabrizio Conti: None declared, Savino Sciascia: None declared, David Jayne Consultant of: Consultant for Astra-Zeneca, Aurinia, BMS, Boehringer-Ingelheim, Chemocentryx, Chugai, CSL, GSK, Infla-RX, Janssen, Novartis, Roche/Genentech, Takeda and Vifor, Augusto Vaglio Consultant of: Consultation honoraria from GSK outside the current work, Giacomo Emmi Consultant of: Consultation honoraria from GSK outside the current work

https://doi.org/10.1136/annrheumdis-2022-eular.4320

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.